News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
536,447 Results
Type
Article (40083)
Company Profile (175)
Press Release (496189)
Multimedia
Podcasts (92)
Webinars (12)
Section
Business (157706)
Career Advice (1790)
Deals (30129)
Drug Delivery (115)
Drug Development (74228)
Employer Resources (139)
FDA (12237)
Job Trends (12002)
News (281760)
Policy (30501)
Tag
Academia (2070)
Accelerated approval (5)
Adcomms (24)
Allergies (79)
Alliances (47799)
ALS (77)
Alzheimer's disease (1257)
Antibody-drug conjugate (ADC) (134)
Approvals (12221)
Artificial intelligence (225)
Autoimmune disease (23)
Automation (11)
Bankruptcy (291)
Best Places to Work (9228)
BIOSECURE Act (20)
Biosimilars (111)
Biotechnology (89)
Bladder cancer (63)
Brain cancer (30)
Breast cancer (226)
Cancer (1962)
Cardiovascular disease (164)
Career advice (1482)
Career pathing (27)
CAR-T (124)
Cell therapy (344)
Cervical cancer (16)
Clinical research (60471)
Collaboration (792)
Company closure (1)
Compensation (479)
Complete response letters (27)
COVID-19 (2588)
CRISPR (40)
C-suite (207)
Cystic fibrosis (80)
Data (1869)
Decentralized trials (2)
Denatured (23)
Depression (42)
Diabetes (251)
Diagnostics (4307)
Digital health (11)
Diversity (7)
Diversity, equity & inclusion (39)
Drug discovery (110)
Drug pricing (122)
Drug shortages (31)
Duchenne muscular dystrophy (91)
Earnings (57964)
Editorial (45)
Employer branding (21)
Employer resources (124)
Events (73563)
Executive appointments (581)
FDA (13271)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (5)
Funding (591)
Gene editing (92)
Generative AI (19)
Gene therapy (288)
GLP-1 (802)
Government (4434)
Grass and pollen (5)
Guidances (54)
Healthcare (13467)
Huntington's disease (22)
IgA nephropathy (29)
Immunology and inflammation (122)
Indications (28)
Infectious disease (2737)
Inflammatory bowel disease (118)
Inflation Reduction Act (9)
Influenza (52)
Intellectual property (88)
Interviews (301)
IPO (12944)
IRA (48)
Job creations (3158)
Job search strategy (1288)
Kidney cancer (8)
Labor market (30)
Layoffs (421)
Leadership (17)
Legal (8029)
Liver cancer (60)
Lung cancer (283)
Lymphoma (139)
Machine learning (7)
Management (42)
Manufacturing (302)
MASH (68)
Medical device (6883)
Medtech (6887)
Mergers & acquisitions (17671)
Metabolic disorders (716)
Multiple sclerosis (68)
NASH (22)
Neurodegenerative disease (89)
Neuropsychiatric disorders (29)
Neuroscience (1752)
NextGen: Class of 2025 (4684)
Non-profit (3144)
Now hiring (24)
Obesity (401)
Opinion (249)
Ovarian cancer (65)
Pain (83)
Pancreatic cancer (73)
Parkinson's disease (138)
Partnered (15)
Patents (204)
Patient recruitment (77)
Peanut (42)
People (43892)
Pharmaceutical (80)
Pharmacy benefit managers (21)
Phase I (18710)
Phase II (26313)
Phase III (20424)
Pipeline (1104)
Policy (163)
Postmarket research (2319)
Preclinical (7608)
Press Release (45)
Prostate cancer (98)
Psychedelics (32)
Radiopharmaceuticals (249)
Rare diseases (349)
Real estate (4461)
Recruiting (59)
Regulatory (20066)
Reports (31)
Research institute (1896)
Resumes & cover letters (278)
Rett syndrome (4)
RNA editing (3)
RSV (47)
Schizophrenia (76)
Series A (105)
Series B (61)
Service/supplier (10)
Sickle cell disease (48)
Special edition (16)
Spinal muscular atrophy (153)
Sponsored (21)
Startups (2877)
State (2)
Stomach cancer (14)
Supply chain (72)
Tariffs (46)
The Weekly (67)
Vaccines (753)
Venture capitalists (38)
Weight loss (295)
Women's health (18)
Worklife (13)
Date
Today (34)
Last 7 days (670)
Last 30 days (2005)
Last 365 days (26301)
2025 (8762)
2024 (28180)
2023 (31725)
2022 (41342)
2021 (44312)
2020 (42452)
2019 (35579)
2018 (27179)
2017 (26639)
2016 (25492)
2015 (29296)
2014 (23179)
2013 (19380)
2012 (20673)
2011 (21312)
2010 (19632)
Location
Africa (740)
Alabama (40)
Alaska (3)
Arizona (130)
Arkansas (9)
Asia (35846)
Australia (5648)
California (4570)
Canada (1645)
China (476)
Colorado (201)
Connecticut (195)
Delaware (121)
Europe (79432)
Florida (726)
Georgia (144)
Hawaii (1)
Idaho (34)
Illinois (411)
India (26)
Indiana (251)
Iowa (9)
Japan (150)
Kansas (79)
Kentucky (20)
Louisiana (11)
Maine (29)
Maryland (769)
Massachusetts (3488)
Michigan (122)
Minnesota (221)
Mississippi (1)
Missouri (57)
Montana (24)
Nebraska (14)
Nevada (45)
New Hampshire (27)
New Jersey (1473)
New Mexico (24)
New York (1367)
North Carolina (764)
North Dakota (5)
Northern California (2021)
Ohio (150)
Oklahoma (7)
Oregon (24)
Pennsylvania (1030)
Puerto Rico (12)
Rhode Island (23)
South America (1052)
South Carolina (13)
South Dakota (1)
Southern California (1734)
Tennessee (60)
Texas (602)
United States (17426)
Utah (110)
Virginia (132)
Washington D.C. (57)
Washington State (393)
West Virginia (2)
Wisconsin (39)
536,447 Results for "novartis pharma schweiz ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Novartis Strikes on M&A, Leading a Line of Big Pharmas With Cash to Spend
Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome sign for the biopharma ecosystem, which has been battered by macro headwinds such as tariffs and the possibility of new drug pricing pressures.
April 30, 2025
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
·
2 min read
·
Tristan Manalac
Patents
Novartis Scrambles to Squelch Copycats as Generics Gain Ground
Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug Entresto.
January 17, 2025
·
2 min read
·
Tristan Manalac
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
Spinal muscular atrophy
Novartis’ Intrathecal Zolgensma Effective in Older Children
After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with an intrathecal formulation intended for older patients.
March 19, 2025
·
6 min read
·
Heather McKenzie
Earnings
Novartis Eyes More Bolt-On Deals in 2025 as Q4 Earnings Easily Beat Consensus
Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.
January 31, 2025
·
2 min read
·
Tristan Manalac
Drug pricing
NJ Court Tosses Novartis’ Lawsuit Against Drug Negotiation Program in Latest Setback for Big Pharma
With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies that have failed in their legal challenges to the Inflation Reduction Act.
October 21, 2024
·
2 min read
·
Tristan Manalac
Press Releases
IGC Pharma Expands CALMA Alzheimer’s Phase 2 Trial with Prestigious Research Site at Butler Hospital’s Memory and Aging Program
April 8, 2025
·
5 min read
Radiopharmaceuticals
5 Big Pharmas Push Boundaries in Radiopharmaceuticals
While Novartis and Bayer got there first, AstraZeneca, Bristol Myers Squibb and Eli Lilly are all vying to bring their radiopharmaceutical assets to a market projected to be worth over $13 billion by 2033.
March 31, 2025
·
9 min read
·
Tristan Manalac
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 53,645
Next
